We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
AstraZeneca has completed the divestment of its 26.7% ownership in Viela Bio, as part of the proposed acquisition of Viela by Horizon Therapeutics. This follows the agreement to divest the shareholding on February 1, 2021.
AstraZeneca has agreed, subject to certain limited exceptions, to divest its 26.7% ownership in Viela Bio, as part of the proposed acquisition of Viela by Horizon Therapeutics.